BR0211827A - Use of il-18 inhibitors in hypersensitivity disorders - Google Patents

Use of il-18 inhibitors in hypersensitivity disorders

Info

Publication number
BR0211827A
BR0211827A BR0211827-0A BR0211827A BR0211827A BR 0211827 A BR0211827 A BR 0211827A BR 0211827 A BR0211827 A BR 0211827A BR 0211827 A BR0211827 A BR 0211827A
Authority
BR
Brazil
Prior art keywords
inhibitors
hypersensitivity disorders
hypersensitivity
disorders
medicament
Prior art date
Application number
BR0211827-0A
Other languages
Portuguese (pt)
Other versions
BRPI0211827B8 (en
BRPI0211827B1 (en
Inventor
Yolande Chvatchko
Marie Kosco-Vilbois
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of BR0211827A publication Critical patent/BR0211827A/en
Publication of BRPI0211827B1 publication Critical patent/BRPI0211827B1/en
Publication of BRPI0211827B8 publication Critical patent/BRPI0211827B8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"USO DE INIBIDORES DE IL-18 EM DISTúRBIOS DE HIPERSENSIBILIDADE". A invenção refere-se ao uso de inibidores de IL-18 na preparação de um medicamento para o tratamento e/ou prevenção de distúrbios de hipersensibilidade e em particular de hipersensibilidade do tipo tardia."Use of IL-18 Inhibitors in Hypersensitivity Disorders". The invention relates to the use of IL-18 inhibitors in the preparation of a medicament for the treatment and / or prevention of hypersensitivity disorders and in particular of late type hypersensitivity.

BR0211827A 2001-08-10 2002-08-01 use of il-18 binding protein (il-18bp) for the manufacture of a drug for the treatment and/or prevention of a type iv hypersensitivity disorder BRPI0211827B8 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP01118811.7 2001-08-10
EP01118811 2001-08-10
EP02100735.6 2002-06-20
EP02100735 2002-06-20
PCT/EP2002/008591 WO2003013577A2 (en) 2001-08-10 2002-08-01 Use of il-18 inhibitors in hypersensitivity disorders

Publications (3)

Publication Number Publication Date
BR0211827A true BR0211827A (en) 2004-08-31
BRPI0211827B1 BRPI0211827B1 (en) 2019-07-23
BRPI0211827B8 BRPI0211827B8 (en) 2021-05-25

Family

ID=26076673

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211827A BRPI0211827B8 (en) 2001-08-10 2002-08-01 use of il-18 binding protein (il-18bp) for the manufacture of a drug for the treatment and/or prevention of a type iv hypersensitivity disorder

Country Status (27)

Country Link
US (1) US20040247598A1 (en)
EP (1) EP1423138B1 (en)
JP (1) JP4301942B2 (en)
KR (1) KR20040030948A (en)
CN (1) CN100500210C (en)
AR (1) AR035274A1 (en)
AU (1) AU2002331376B2 (en)
BR (1) BRPI0211827B8 (en)
CA (1) CA2456247C (en)
CY (1) CY1116137T1 (en)
DK (1) DK1423138T3 (en)
EA (1) EA006745B1 (en)
ES (1) ES2533253T3 (en)
HK (1) HK1069780A1 (en)
HR (1) HRP20040071B1 (en)
HU (1) HU230377B1 (en)
IL (2) IL160230A0 (en)
ME (1) ME00547B (en)
MX (1) MXPA04001230A (en)
NO (1) NO335688B1 (en)
PL (1) PL227130B1 (en)
PT (1) PT1423138E (en)
RS (1) RS52224B (en)
SI (1) SI1423138T1 (en)
UA (1) UA78516C2 (en)
WO (1) WO2003013577A2 (en)
ZA (1) ZA200400442B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5069000B2 (en) * 2004-06-30 2012-11-07 敦生 関山 Non-inflammatory stress response indicator and use thereof
DK1885753T3 (en) 2005-06-03 2011-10-03 Ares Trading Sa Preparation of Recombinant II-18 Proteins
DK1891088T3 (en) 2005-06-10 2012-01-30 Ares Trading Sa Process for Purification of an IL-18 Binding Protein
MY157173A (en) 2006-05-25 2016-05-13 Glaxo Group Ltd Modified humanised anti-interleukin-18
CN103458904B (en) * 2010-12-16 2016-09-28 株式会社明治 The thalline fraction of Lactobacillus gasseri purposes in manufacturing the compositions for alleviating delayed allergy

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922737A (en) * 1996-02-21 1999-07-13 Hoechst Marion Roussel, Inc. Substituted N-methyl-N-(4-(4-(1H-Benzimidazol-2-YL-amino) piperidin-1-YL)-2-(arlyl) butyl) benzamides useful for the treatment of allergic diseases
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
DE69925581T2 (en) * 1998-03-09 2006-04-27 Vertex Pharmaceuticals Inc., Cambridge 1,2-DIAZEPANDERIVATE AS INHIBITORS OF INTERLEUKIN-1BETA CONVERTING ENZYME
CA2276216A1 (en) * 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
KR100537558B1 (en) * 1998-09-01 2005-12-19 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 Interleukin 18-binding protein
AU5282600A (en) * 1999-05-20 2000-12-12 Hyseq, Inc. Interleukin-1 hy2 materials and methods
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders

Also Published As

Publication number Publication date
HU230377B1 (en) 2016-03-29
ME00547B (en) 2011-12-20
US20040247598A1 (en) 2004-12-09
PT1423138E (en) 2015-02-09
EP1423138B1 (en) 2014-12-24
RS52224B (en) 2012-10-31
HRP20040071A2 (en) 2004-10-31
IL160230A (en) 2014-11-30
NO335688B1 (en) 2015-01-19
CN1568193A (en) 2005-01-19
BRPI0211827B8 (en) 2021-05-25
PL227130B1 (en) 2017-10-31
HUP0401323A3 (en) 2006-01-30
YU11904A (en) 2006-08-17
CN100500210C (en) 2009-06-17
EA200400296A1 (en) 2004-06-24
HRP20040071B1 (en) 2015-08-28
AU2002331376B2 (en) 2007-06-14
WO2003013577A2 (en) 2003-02-20
WO2003013577A3 (en) 2003-09-25
CA2456247C (en) 2013-09-10
HUP0401323A2 (en) 2004-10-28
JP2005501080A (en) 2005-01-13
ZA200400442B (en) 2005-03-30
BRPI0211827B1 (en) 2019-07-23
DK1423138T3 (en) 2015-02-23
EA006745B1 (en) 2006-04-28
NO20040370L (en) 2004-03-23
UA78516C2 (en) 2007-04-10
PL368231A1 (en) 2005-03-21
EP1423138A2 (en) 2004-06-02
HK1069780A1 (en) 2005-06-03
CA2456247A1 (en) 2003-02-20
ES2533253T3 (en) 2015-04-08
SI1423138T1 (en) 2015-04-30
MXPA04001230A (en) 2004-05-27
IL160230A0 (en) 2004-07-25
AR035274A1 (en) 2004-05-05
CY1116137T1 (en) 2017-02-08
KR20040030948A (en) 2004-04-09
JP4301942B2 (en) 2009-07-22

Similar Documents

Publication Publication Date Title
BR9911666A (en) Pharmaceutical combination, use of the combination, process for treating an inflammatory disease in a person suffering from or susceptible to such disease, and pharmaceutical composition
PT1181027E (en) DIETETIC OR PHARMACEUTICAL COMPOSITION FOR USE IN THE PREVENTION OR TREATMENT OF HYPEROXALURY
BR0213358A (en) Flibanserin use
BR0212374A (en) Oxintomodulin for the prevention or treatment of overweight
BR0214705A (en) Composition, use, method for prevention or treatment of neurodegenerative disease, and kit
BR0308663A (en) Use of il-18 inhibitors for the treatment and / or prevention of peripheral vascular diseases.
BR0207961A (en) Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases.
BR9812753A (en) Pharmaceutical combination, use thereof, process for treating an inflammatory disease, and pharmaceutical composition
PT1313489E (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF BEHCET MUCOSITE, STOMATITIS AND SINDROMA
BRPI0407234A (en) Substituted heterocycles
IT1302365B1 (en) USE OF CARNITINE AND RESVERATROL TO PRODUCE A COMPOSITION FOR THE PREVENTION OR THERAPEUTIC TREATMENT OF BRAIN ALTERATIONS
BR0312165A (en) Use of taurine for the treatment of alopecia
BR0108514A (en) Use of il-18 inhibitors
BR0110506A (en) Use of il-18 inhibitors for the treatment and / or prevention of atherosclerosis.
BRPI0412919A (en) combination of mglur2 antagonist and ache inhibitor for the treatment of chronic and / or acute neurological disorders
HRP20050579B1 (en) New synergistic combination comprising roflumilast and formoterol
PT1414473E (en) ORAL ADMINISTRATION COMPOSITIONS FOR THE TREATMENT OF CABELUDE LEATHER DISTURBLES
BR0206819A (en) Use of il-18 inhibitors for treatment and / or prevention of heart disease.
BR0211827A (en) Use of il-18 inhibitors in hypersensitivity disorders
BR9911005A (en) Use of ozone for the preparation of drugs for the treatment of dental caries
BR0115983A (en) Use of sarp-1 for the treatment and / or prevention of scleroderma.
BR0210007A (en) Use of il-18 inhibitors for treatment or prevention of central nervous system injury
BR0210910A (en) Imidazotriazinone derivatives and their application against inflammatory processes and / or immune diseases
BR0111785A (en) Compositions and methods for treating candidiasis
NO20003866D0 (en) Herbal antiviral agent

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: LABORATOIRES SERONO S.A. (CH)

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: MERCK SERONO S.A. (CH)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 01/08/2002 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 01/08/2022